Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06572215

DYNAMic Renal Assessment: NOvel Methods to Assess KIDNEY Functional Reserve

This is a feasibility study to assess new, more practical ways of measuring renal reserve.

Recruiting

Interested in participating?

Request Info

Key information

Age range

40 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

King's College Hospital

London, United Kingdom

Location status: Recruiting

Location contact

Pearl Dulawan

CONTACT

[email protected]

02032995658

About this study

Quantification of glomerular filtration rate (GFR) over time is the standard assessment of kidney function. In clinical practice, the endogenous marker, 'serum creatinine' concentration, is used as a static assessment of kidney function to estimate GFR. However, serum creatinine fails to increase until at least 50% of kidney tissue is lost,[2] thus is an inadequate indicator of early CKD.

GFR like many other physiological processes is not static and augments temporarily to stimuli such as exercise and protein intake, by up to 25% from baseline in healthy individuals.[3] Similar to cardiac function stress tests which predict adverse outcomes, inability to respond to renal stressors or 'reduced renal reserve' has been demonstrated to occur prior to development of CKD (e.g. in patients with diabetes and previous acute kidney injury (AKI)) and is associated with vulnerability to future AKI, despite the presence of apparently normal kidney function measured by serum creatinine concentration.[4] Renal reserve is lost with progressive CKD,[4] and has also been demonstrated to relate to severity of histological lesions.[5]

Current measurements of renal reserve (stimulated increase in GFR due to augmented renal blood flow above basal fasting values) involve administration of a compound that is freely filtered by the glomerulus, unaffected by tubular function and is physiologically inert, with assessment before and after an oral protein load or amino acid infusion which induces arterial vasodilation, increasing renal blood flow and GFR

The study proposes a comparison of two novel methods of 'dynamic renal function testing' with renal reserve testing.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion:

  • Patients with sickle cell nephropathy, diagnosed clinically or histologically. Sickle Cell patients will be confirmed Hb SS and eGFR (CKD-EPI) ≥ 135 ml/min/1.73m2 OR
  • Previous living kidney donation
  • Age ≥ 4No contraindication or known allergy to any trial medications.
  • Willing and able to provide written informed consent

Exclusion:

  • Aged < 40
  • Unable or unwilling to provide informed consent
  • Breastfeeding or pregnant women
  • Patients involved in other interventional research studies.

Treatment and study plan

Dapagliflozin

Drug

On Day 3 to 16, participants will take 10mg dapaglifozin (SGLT-2 inhibitor) orally once daily.

Primary outcomes

  1. Change in eGFR from baseline to 2hours after oral protein load

    Time frame: 2 hours

Study contacts

Contact information is provided by the study sponsor or research team.

Kate Bramham, Doctor

CONTACT

[email protected]

0203 299 9000

Sponsors and collaborators

Lead sponsor

King's College Hospital NHS Trust

Other

Collaborators

  • King's College London

Registry information

Acronym: DYNAMO

Important dates

Study start
2023
Primary completion
2027
Study completion
2027
First posted
Aug 27, 2024
Registry last updated
Apr 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.